TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00236925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose Hydrocortisone
Description: Hydrocortisone 10 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low dose Hydrocortisone
Description: Hydrocortisone 10 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01560923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Given twice daily (1200 mg total) by mouth for 6 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Description: Sipuleucel-T will be administered as standard of care. Given by infusion over 60 minutes at Week 0, 2 and 4. Patients will undergo leukapheresis at weeks 0, 2, and 4 with sipuleucel-T infused 3 days later (i.e. Monday/Thursday; Tuesday/Friday).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sipuleucel-T
Description: Sipuleucel-T will be administered as standard of care. Given by infusion over 60 minutes at Week 0, 2 and 4. Patients will undergo leukapheresis at weeks 0, 2, and 4 with sipuleucel-T infused 3 days later (i.e. Monday/Thursday; Tuesday/Friday).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given in same manner as Indoximod; 1200 mg per day by mouth.
Study: NCT02542384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CR845 IV 1 mcg/kg
Description: CR845 IV 1 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed. Saline infusion (IV 0.45%) for fluid replenishment will be provided.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CR845 IV 0.5 mcg/kg
Description: CR845 IV 0.5 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.~Saline infusion (IV 0.45%) for fluid replenishment will be provided.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Placebo IV will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.~Saline infusion (IV 0.45%) for fluid replenishment will be provided.
Study: NCT01115530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Lower extremity resistance exercise (leg press/knee extension) twice per week for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Lower extremity resistance exercise (leg press/knee extension) twice per week for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein and HMB (see below) supplement
Description: Ingested twice daily for 12 weeks Active components include: Protein and B-hydroxy-B -methylbutyrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein and HMB (see below) supplement
Description: Ingested twice daily for 12 weeks Active components include: Protein and B-hydroxy-B -methylbutyrate
Study: NCT02876835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: The initial dose or oral daprodustat for ESA naïve subjects is based on Hgb and for ESA users is based on prior ESA dose. The dose is adjusted thereafter in order to achieve the target range.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: The initial dose of darbepoetin alfa to be administered for SC injection for ESA naïve subjects is based in Hgb and weight, and for ESA users is based on converting the prior ESA dose to the nearest available study darbepoetin alfa dose. The dose is adjusted thereafter in order to achieve the target range. IV darbepoetin alfa can be considered for participants transitioning to hemodialysis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Therapy
Description: Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Therapy
Description: Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
Study: NCT04535180

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-energy X-ray absorptiometry (DXA)
Description: Body composition will be measured using whole-body DXA (GE Lunar iDXA, GE Healthcare Lunar, Madison, Wisconsin, U.S.A.). Extremity skeletal muscle mass will be calculated using the values measured via the DXA; ASM will be calculated as the sum of skeletal muscle mass in the arms and legs, assuming that the mass of lean soft tissue is a skeletal muscle. Appendicular skeletal mass index (ASM/Ht2 ) will be determined as the sum of the arm and leg lean mass (kg)/height2 (m2~). BMD will be measured in lumbar spine and bilateral hip by the same DXA device (GE Lunar iDXA, GE Healthcare Lunar, Madison, Wisconsin, U.S.A.)
Study: NCT00407654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: Given intravenously
Study: NCT03724734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive DBS
Description: We will use our custom-built externalized research system (ERS) to allow recordings and stimulation. The device is small and lightweight and communicates wirelessly with a personal computer. The electrical connections to the DBS leads will be through temporary extensions with appropriate mechanical slack. To allow for stimulation return, a conductive clip to the ERS case will be connected to a conducting (ECG) pad placed over chest. Periodic impedance checks will ensure this connection is robust through the course of the experiment. The patient can be ambulant whilst wearing the device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional DBS
Description: We will use our custom-built externalized research system (ERS) to deliver continuous conventional stimulation.
Study: NCT04411953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol Tablets, Mylan Pharmaceuticals Inc.
Description: single dose, 2 mg Haloperidol tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol Tablets, Cycle Pharmaceuticals Ltd
Description: single dose, 2 mg Haloperidol tablet
Study: NCT02838095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap
Description: A 1-hour daytime nap opportunity
Study: NCT02862405

Intervention type: OTHER
Intervention: vision tests

Intervention type: OTHER
Intervention: vision tests

Intervention type: OTHER
Intervention: vision tests
Study: NCT01512563

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary stent
Description: palliative treatment for malignant patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biliary stent
Description: palliative treatment for malignant patients
Study: NCT04411628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3819253
Description: Administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.
Study: NCT02699957

Intervention type: PROCEDURE
Intervention: Left Atrial Appendage Occlusion
Description: Patients undergoing percutaneous/epicardial intervention for left atrial appendage occlusion.
Study: NCT00732251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol: 300-600 mg/day over a 24 month period
Study: NCT00691990

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total thyroidectomy
Description: Comparison of the safety and cost-effectiveness of classic thyroidectomy with or without drains

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total thyroidectomy
Description: Comparison of the safety and cost-effectiveness of classic thyroidectomy with or without drains
Study: NCT00805025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZLI
Description: 75 mg aztreonam for inhalation solution (AZLI), administered 3 times daily using the PARI Investigational eFlow® Nebulizer System (with a minimum of 4 hours between doses) following administration of a short-acting bronchodilator
Study: NCT01961206

Intervention type: OTHER
Intervention: bacteremia caused by ESBL producing E.coli or K.pneumoniae
Description: community-onset bacteremia caused by ESBL producing E.coli or K.pneumoniae
Study: NCT03817866

Intervention type: DIAGNOSTIC_TEST
Intervention: BRAHMS CgA II KRYPTOR
Description: The BRAHMS CgA II KRYPTOR kit is an automated immunofluorescent assay for the quantitative determination of the concentration of CgA in human serum.~The assay is to be used as an aid in monitoring disease progression during the course of disease and treatment in patients with GEP-NETs (grade 1 and grade 2).~Serial testing for patient BRAHMS CgA II KRYPTOR assay values should be used in conjunction with other clinical methods for monitoring GEP-NETs (grade 1 and grade 2).
Study: NCT02774616

Intervention type: DEVICE
Group type: OTHER
Intervention: Ilivia ICD Family
Description: pre-defined device programming, measurements and follow-up schedule

Intervention type: DEVICE
Group type: OTHER
Intervention: Ilivia ICD Family
Description: pre-defined device programming, measurements and follow-up schedule

Intervention type: DEVICE
Group type: OTHER
Intervention: Plexa ICD lead
Description: predefined follow-up schedule

Intervention type: DEVICE
Group type: OTHER
Intervention: Plexa ICD lead
Description: predefined follow-up schedule
Study: NCT02510781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 75mg/m2 d1 evry 21days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 d1 evry 21days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2 d1 evry 21days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 6mg/kg(loading dosage is 8mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 6mg/kg(loading dosage is 8mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area Under Curve(AUC)=6 d1 evry 21days
Study: NCT04261504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IBMT
Description: mindful presence in a non-judgmental way

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RT
Description: progressive muscle relaxation
Study: NCT01980420

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic sleeve gastrectomy
Description: Conventional laparoscopic sleeve gastrectomy using EndoFLIP® probe to provide measures on the distensibility of gastro-esophageal junction (GEJ) and gastric tube.
Study: NCT03772470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1X airtime incentive
Description: An incentive given in the form of airtime

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2X airtime incentive
Description: An incentive given in the form of airtime

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lottery airtime incentive
Description: An incentive given in the form of airtime
Study: NCT00430482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 12 weekly sessions and 3 booster sessions of cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Counseling
Description: 12 weekly sessions and 3 booster sessions of individual counseling
Study: NCT01910350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kin KeeperSM Cancer Prevention Intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Study: NCT01486797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-A12
Description: Pilot Group (NOX-A12 single agent, and combined with BR):~* 3 cohorts of 3 patients will receive treatment with NOX-A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX-A12 and BR begins.The combination of NOX-A12 and BR will follow a dose titration design beginning at 1 mg/kg NOX-A12 (cycle 1), proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX-A12 in combination with BR. This is followed by consolidation in cycles 4-6 when NOX-A12 will be kept at the highest individually titrated dose.~Expansion Group (NOX-A12 in combination with BR):~* Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group.
Study: NCT00382018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: No administration details available

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: No administration details available

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: No administration details available

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: No administration details available
Study: NCT03463798

Intervention type: DEVICE
Intervention: Sonar
Description: Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly

Intervention type: DEVICE
Intervention: Sonar
Description: Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly

Intervention type: DEVICE
Intervention: Structured light plethysmography (SLP)
Description: Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly

Intervention type: DEVICE
Intervention: Structured light plethysmography (SLP)
Description: Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly
Study: NCT03862365

Intervention type: GENETIC
Intervention: Nerve conduction Studies
Description: Patients will be genotyped for comparison of patients With and without pain, With different clinical subgroups as mentioned.

Intervention type: GENETIC
Intervention: Nerve conduction Studies
Description: Patients will be genotyped for comparison of patients With and without pain, With different clinical subgroups as mentioned.

Intervention type: GENETIC
Intervention: Nerve conduction Studies
Description: Patients will be genotyped for comparison of patients With and without pain, With different clinical subgroups as mentioned.

Intervention type: GENETIC
Intervention: Nerve conduction Studies
Description: Patients will be genotyped for comparison of patients With and without pain, With different clinical subgroups as mentioned.

Intervention type: GENETIC
Intervention: Nerve conduction Studies
Description: Patients will be genotyped for comparison of patients With and without pain, With different clinical subgroups as mentioned.

Intervention type: GENETIC
Intervention: Nerve conduction Studies
Description: Patients will be genotyped for comparison of patients With and without pain, With different clinical subgroups as mentioned.
Study: NCT02630446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: in-home respite care program
Description: During the respite care period, lasting at least five days, a trained or experienced care worker for persons with dementia takes over all caregiving tasks while the informal caregiver is absent. The care worker thus temporary moves into the house of the person with dementia. The care worker also writes down his/her observations in a diary as well as daily experiences and strategies on how to manage the difficult behaviors the caregivers listed before. So additionally to the provision of respite, this program also includes caregiver support and psycho-education. This support enables the caregiver to validate theirs perceptions, to learn how to deal with difficult behaviors and to feel understood by somebody.
Study: NCT02840110

Intervention type: OTHER
Intervention: ACTR T Cell Product
Study: NCT01251263

Intervention type: DRUG
Group type: OTHER
Intervention: Estradiol or Placebo
Description: Estradiol 1mg twice daily or placebo starting on the last day of OC and continuing during the HFI (total of 9 doses).

Intervention type: DRUG
Group type: OTHER
Intervention: Estradiol or Placebo
Description: Estradiol 1mg will be taken twice daily starting with the last day of pills and the 4 days of the HFI(total of 9 doses)
Study: NCT02082899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator EBI-005 5 mg/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study: NCT02811549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HiResolution Bionic Cochlear Implant
Description: HiRes 90K™ Advantage implant with HiFocus™ 1J electrode, HiRes 90K™ Advantage implant with the HiFocus Helix™ electrode, HiRes 90K™ Advantage implant with the HiFocus™ Mid-Scala electrode or the HiRes™ Ultra Implant with the HiFocus™ Mid-Scala electrode will be implanted in adults with eligible hearing profile.
Study: NCT03573609

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supranav
Description: Continuous supraglottic suction device for patients with orotraqueal intubation an mechanical ventilation
Study: NCT02887014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPECIFIC VERBAL INSTRUCTIONS
Description: Participants will be randomized either to get detailed instructions verbally by the medico-paramedical staff of the participating centers (physicians or nurses) before starting bowel preparation (Group A) or to get ordinary instructions as usual in each of the participating centers (Group B). Instructions provided to Group A will include details about the procedure of bowel preparation, its potential side effects and the importance of the adequate preparation (Appendix)
Study: NCT01279850

Intervention type: DRUG
Intervention: Pregabalin (Lyrica) capsule
Description: Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily.
Study: NCT03713749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot esophagectomy (RE)
Description: Patients in RE group will receive Robotic-assisted surgery in thoracic phase.
Study: NCT04353466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quantitative chemical shift imaging (QCSI)
Description: Poor scores of QCSI with Fat Fraction below the cut off point of 0.3 which is considered bone at risk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elelyso
Description: intravenous (IV) infusions of Elelyso
Study: NCT03517891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WIC+
Description: intervention was based on the Health Self-Empowerment Theory. It will be adapted for the web-based platform using the Persuasive Technology and Persuasive System Design models. These models focus on the human-computer interface and how technology can/is used as a persuasive tool for behavior change. We will also include Bandura's Social Cognitive Theory.~The intervention will be delivered through the combination of:~educational modules provided through an interactive distance learning platform designed to provide learning experiences using multiple modalities; short messaging platforms to promote adoption of healthy behaviors and use of the educational platform; one to one sessions with the interventionist over the telephone.
Study: NCT03484286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTILOGG
Description: OPTILOGG is a CE marked class 1m medical device. It consists of a tablet computer and a wirelessly connected weight scale. The system will have some patient specific information regarding the flexible (loop-) diuretics scheme.~The patient will be asked to step on the weight scale daily, and will be shown to some brief information on how to live better with HF, as well as the recommended dose of diuretics that specific day. Every five days the patient will answer three questions about his/her symptoms, namely shortness of breath, fatigue and peripheral edema. The system also contains information that the patient can study at his/her leisure. If the system detects a deterioration in HF status, the patient is encouraged to contact his/her health care provider via telephone.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Patients in the control group will be subject to standard heart failure care.
Study: NCT03762720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physium treatment
Description: patients will receive five sessions of physium therapy at 80 millibars in 30 minutes for one month in muscle injury and diagnosed by ultrasound and Shear Wave Elastography.